Noncoding RNAs as regulators of STAT3 pathway in gastrointestinal cancers: Roles in cancer progression and therapeutic response
M Ashrafizadeh, CD Mohan… - Medicinal research …, 2023 - Wiley Online Library
Gastrointestinal (GI) tumors (cancers of the esophagus, gastric, liver, pancreas, colon, and
rectum) contribute to a large number of deaths worldwide. STAT3 is an oncogenic …
rectum) contribute to a large number of deaths worldwide. STAT3 is an oncogenic …
[HTML][HTML] Therapeutic effects of coumarins with different substitution patterns
V Flores-Morales, AP Villasana-Ruíz, I Garza-Veloz… - Molecules, 2023 - mdpi.com
The use of derivatives of natural and synthetic origin has gained attention because of their
therapeutic effects against human diseases. Coumarins are one of the most common …
therapeutic effects against human diseases. Coumarins are one of the most common …
Long non-coding RNAs (lncRNAs) in hepatocellular carcinoma progression: Biological functions and new therapeutic targets
Liver is an important organ in body that performs vital functions such as detoxification. Liver
is susceptible to development of cancers, and hepatocellular carcinoma (HCC) is among …
is susceptible to development of cancers, and hepatocellular carcinoma (HCC) is among …
CXCR4 expression is elevated in TNBC patient derived samples and Z-guggulsterone abrogates tumor progression by targeting CXCL12/CXCR4 signaling axis in …
N Gupta, CD Mohan, MK Shanmugam, YY Jung… - Environmental …, 2023 - Elsevier
Environmental factors such as exposure to ionizing radiations, certain environmental
pollutants, and toxic chemicals are considered as risk factors in the development of breast …
pollutants, and toxic chemicals are considered as risk factors in the development of breast …
[HTML][HTML] Discovery of Pyrimidine-and Coumarin-Linked Hybrid Molecules as Inducers of JNK Phosphorylation through ROS Generation in Breast Cancer Cells
NY Kim, D Vishwanath, Z Xi, O Nagaraja… - Molecules, 2023 - mdpi.com
Human epidermal growth factor receptor 2 (HER2)-positive breast cancer exhibits early
relapses, poor prognoses, and high recurrence rates. Herein, a JNK-targeting compound …
relapses, poor prognoses, and high recurrence rates. Herein, a JNK-targeting compound …